BioCentury
ARTICLE | Clinical News

Solanezumab: Phase III data

July 27, 2015 7:00 AM UTC

Eli Lilly and researchers at the University of California San Diego reported data from a pre-specified secondary delayed-start analysis of pooled data from 1,322 patients with mild AD in the Phase III EXPEDITION, EXPEDITION2 and EXPEDITION-EXT trials of solanezumab showing that patients who started treatment immediately retained a benefit in cognitive and functional treatment effects compared to patients who delayed treatment by 80 weeks. The researchers said the results “are consistent with a potential disease-modifying effect of solanezumab” and support the use of the delayed-start method to determine the potential effects of an AD treatment on the underlying disease progression of AD. ...